LIDDS AB (LIDDS) AI Stock Analysis

• Market Cap: €8.13M
• Dividend Yield: N/A
• Average Volume (3M): 48.19K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.33
• Revenue Growth: N/A
• EPS Growth: 88.59%
• Country: SE
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 136,463,330
• 10 Day Avg. Volume: 51,372
• 30 Day Avg. Volume: 48,191
• PEG Ratio: 0.03
• Price to Book (P/B): 2.24
• Price to Sales (P/S): 432.85
• P/FCF Ratio: -2.51
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 37 Underperform
• Price Target: ―

LIDDS AB's overall stock score is significantly impacted by its weak financial performance due to persistent losses and negative cash flow. Technical analysis further suggests bearish momentum with prices below key moving averages. Valuation concerns arise from a negative P/E ratio and lack of dividend yield, indicating high risk. The company's stability is challenged by the need for improved profitability and operational efficiency.

LIDDS AB Business Overview & Revenue Model

Company Description

LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an immunotherapy; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. LIDDS AB (publ) has a collaboration agreement with PharmIdea SIA to focus on anti-cancer drugs and sterile formulations. The company is based in Uppsala, Sweden.

How the Company Makes Money

LIDDS AB generates revenue through licensing agreements, collaborations, and partnerships with pharmaceutical companies interested in utilizing its NanoZolid® technology for their drug development projects. The company earns upfront payments, milestone payments, and royalties based on the commercial success of products developed using their technology. Additionally, LIDDS might engage in contract research and development services, offering its expertise in drug formulation and delivery. These strategic alliances and service offerings are crucial for the company's financial performance and growth in the competitive pharmaceutical industry.

LIDDS AB Financial Statement Overview

Summary

LIDDS AB faces significant challenges across its financial statements. The income statement reflects ongoing operational and profitability issues, while the balance sheet remains debt-free but fails to translate into positive returns. Cash flow pressures persist, with negative free cash flow indicating liquidity challenges. The company needs to focus on improving its revenue growth and operational efficiency to enhance its financial health.

Income Statement

LIDDS AB has struggled with consistently negative gross and net profit margins over multiple years, indicating ongoing profitability challenges. The revenue growth rate was positive for 2024 due to a very low base in 2023, but overall, the company has not shown sustainable revenue growth. EBIT and EBITDA margins are also negative, further highlighting operational inefficiencies.

Balance Sheet

The company has a strong equity position with no debt, leading to a solid equity ratio. However, the return on equity is negative due to persistent losses, which is a concern. The balance sheet shows stability in terms of equity but highlights the challenge of translating this into profitability.

Cash Flow

Free cash flow remains negative, although the company has managed to reduce its cash flow deficit over the years. The operating cash flow to net income ratio is negative, reflecting cash outflows exceeding net losses. The company has not been able to generate positive free cash flow consistently, which limits its financial flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.00K	32.00K	0.00	1.89M	3.55M	345.00K
Gross Profit	-3.67M	-3.40M	-12.92M	-36.62M	-25.78M	-24.79M
EBITDA	-4.04M	-4.49M	-39.67M	-36.11M	-36.81M	-32.20M
Net Income	-3.95M	-5.94M	-40.21M	-36.86M	-37.27M	-32.33M
Balance Sheet
Total Assets	2.81M	8.16M	17.66M	25.92M	55.58M	54.20M
Cash, Cash Equivalents and Short-Term Investments	2.35M	5.51M	13.51M	5.26M	34.00M	36.07M
Total Debt	0.00	0.00	0.00	3.99M	0.00	0.00
Total Liabilities	647.00K	1.98M	3.76M	10.57M	7.07M	11.40M
Stockholders Equity	2.17M	6.18M	13.90M	15.35M	48.51M	42.81M
Cash Flow
Free Cash Flow	-4.83M	-5.53M	-26.50M	-36.40M	-45.04M	-31.17M
Operating Cash Flow	-4.76M	-5.43M	-26.22M	-35.59M	-42.64M	-27.42M
Investing Cash Flow	-72.00K	11.03M	-282.00K	-810.00K	-2.40M	-3.75M
Financing Cash Flow	-824.00K	-280.00K	34.76M	7.66M	42.97M	59.64M

LIDDS AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:LIDDS, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.07, and below the 200-day MA of 0.09, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.69 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:LIDDS.

LIDDS AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LARK	52 Neutral	kr50.30M	―	―	8.10%	-94.12%	-25.83%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LIDDS	37 Underperform	€8.13M	―	-112.33%	―	―	88.59%
STABL	34 Underperform	kr15.22M	―	-83.38%	―	―	68.74%
QUIA	32 Underperform	kr6.80M	―	-135.41%	―	-100.00%	50.33%